iSchemaView's Rapid Neuroimaging Platform Approved in Japan


July 8, 2019—iSchemaView announced that it has received registration approval under the Japanese Pharmaceutical Affairs Law through third-party review by the Japanese Association for the Advancement of Medical Equipment for its Rapid imaging platform. The Rapid technology is now available to hospitals across Japan, with the support of Micron, the Japanese distributor of Rapid.

According to the company, Rapid is designed to provide physicians with fast, fully automated, and easy-to-interpret imaging that facilitates clinical decision-making around stroke. The Rapid artificial intelligence (AI) framework combines deep learning, machine learning, and expert feature extraction. The device provides sensitivity and specificity across stroke modules (CT perfusion, MR diffusion and perfusion, CTA, CT ASPECT scoring). Results are then delivered by the Rapid Intelligence Services platform via PACS, email, text, the Rapid app, or corporate partner workflow systems.

In the company's announcement, Manabu Inoue, MD, from the National Cerebral & Cardiovascular Center in Osaka, Japan, commented, “Stroke remains the fourth most common cause of death in Japan, and as the population ages, stroke is likely to become an increasing health burden on the country. With Rapid’s AI-powered imaging technology, we will be able to better address our patients to provide them with the best routes of care, improving their chances of recovery.”


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.